Abstract 382P
Background
The tribal populations throughout India have remained socially and culturally alienated from mainstream Indian society until developmental and conservation activities in tribal areas forced interactions between them. The precancerous oral lesion is a major public health problem among South Indian tribes in Kerala state. The aim of this study was to explore oral health disparities among the underprivileged Paniya and the privileged Kurichiya tribes of Wayanad, South India from the Precancerous oral lesions perspective.
Methods
A cross sectional survey was done among 600 Kurichiya tribes and 400 Paniya tribal populations of Wayanad District, India from January 2013 to June 2013 after approval from the Institutional ethical committee. A pretested structured questionnaire was used to collect data regarding study variables. Oral health survey form was used to record the oromucosal status of the study population after obtaining informed consent.
Results
In this study Precancerous oral lesions was found to be far more prevalent among the underprivileged Paniya tribes than among the privileged Kurichiya tribes (P < 0.0001). The prevalence of leukoplakia was found to be 42% amongst the Paniya tribes. This was much higher than the 2% found among the Kurichiya tribes. Among the Paniya tribes a statistically significant relationship was observed between Precancerous oral lesions and poor access to oral health care (P < 0.001).
Conclusions
The Paniya tribe is a distinct community with their own cultural beliefs, habits, and attitudes. High prevalence of precancerous oral lesions in the underprivileged population was due to tobacco usage and alcohol consumption and lack of awareness regarding the deleterious effects of the products used. Knowledge of these differences can be used to provide appropriate health education programs suitably targeted to reduce the use of the known risk factors for oral cancer.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The author.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
122P - Distinct transcriptomic immune profiling and clinicopathological features of cribriform morphology in colorectal adenocarcinomas
Presenter: Abdelhakim Khellaf
Session: Poster Display
Resources:
Abstract
123P - Spatial molecular profiling identifies FGF20 upregulation on cancer-associated fibroblast and FGFR2-PI3K/Akt activation in tumor cells of sporadic early-onset colon cancer
Presenter: Dave Hoon
Session: Poster Display
Resources:
Abstract
124P - Characteristics, prognosis and therapeutic effects of non-V600 BRAF mutated colorectal cancer
Presenter: Lalida Arsa
Session: Poster Display
Resources:
Abstract
125P - Final results of APOLLON-11 and SOYUZ-APOLLON study: Multicentre prospective observational post-authorization study of bevacizumab biosimilar in patients with metastatic colorectal cancer in real-world practice
Presenter: Alexey Tryakin
Session: Poster Display
Resources:
Abstract
126P - From tumor height (TH) to tumor regression grade (TRG) in locally advanced rectal cancers (LARC) during total neadjuvant therapy (TNT): A retrospective analysis
Presenter: Valeria Pusceddu
Session: Poster Display
Resources:
Abstract
127P - A meta-analysis of efficacy and safety from head-to-head first-line (1L) trials of epidermal growth factor receptor inhibitors (EGFRIs) versus bevacizumab in combination with chemotherapy (CT) doublets in patients with RAS wild-type (WT) metastatic colorectal cancer (mCRC) by sidedness
Presenter: Takayuki Yoshino
Session: Poster Display
Resources:
Abstract
128TiP - A phase II study of cadonilimab + FOLFOXIRI and bevacizumab as initial therapy for unresectable proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC)
Presenter: Rongbo Lin
Session: Poster Display
Resources:
Abstract
140P - Prevalence of claudin-18 isoform 2 (CLDN18.2) positivity in locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mg/GEJ) adenocarcinoma in patients (pts) in the Asia region: Phase III SPOTLIGHT and GLOW studies
Presenter: Hoo Hwoei Fen Soo
Session: Poster Display
Resources:
Abstract
141P - Early phase trials outcomes in refractory upper GI cancers: A 10-year analysis from the SCRI UK phase I unit
Presenter: Antonella Cammarota
Session: Poster Display
Resources:
Abstract
142P - The survival impact of the addition of durvalumab to cisplatin/gemcitabine in advanced biliary tract cancer: A real-world, retrospective, multicentric study
Presenter: Silvia Foti
Session: Poster Display
Resources:
Abstract